Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ: NTRA )

162.39 +0.40 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 286,702
Open 161.99
Bid (Size) 161.95 (1)
Ask (Size) 162.94 (1)
Prev. Close 161.99
Today's Range 160.97 - 163.62
52wk Range 58.53 - 175.63
Shares Outstanding 132,020,816
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next
Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool

Performance

YTD
+162.26%
+162.26%
1 Month
-1.22%
-1.22%
3 Month
+29.92%
+29.92%
6 Month
+45.79%
+45.79%
1 Year
+165.47%
+165.47%

More News

Read More
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%
Via Benzinga
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Exploring NASDAQ:NTRA's high growth characteristics.
Via Chartmill
Looking Into Natera's Recent Short Interest
Via Benzinga
Analyst Expectations For Natera's Future
Via Benzinga
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
From Natera, Inc.
Via Business Wire
Natera Analysts Increase Their Forecasts Following Upbeat Results
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
From Natera, Inc.
Via Business Wire
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
Natera Issues Statement on Guardant Health Litigation
From Natera, Inc.
Via Business Wire
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
From Natera, Inc.
Via Business Wire
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stocks Edge Higher, Dollar Hits 1-Year Peak, Bitcoin Soars To $93,000: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Natera Reports Third Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What's Driving Markets Tuesday?
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.